Dogwood Therapeutics, Inc. (DWTX)
| Market Cap | 61.79M +544.1% |
| Revenue (ttm) | n/a |
| Net Income | -28.32M |
| EPS | -2.18 |
| Shares Out | 33.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,206 |
| Open | 1.680 |
| Previous Close | 1.700 |
| Day's Range | 1.595 - 1.855 |
| 52-Week Range | 1.280 - 9.500 |
| Beta | 1.70 |
| Analysts | Buy |
| Price Target | 14.00 (+656.76%) |
| Earnings Date | May 14, 2026 |
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DWTX stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 656.76% from the latest price.
News
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
Dogwood Therapeutics Earnings release: Q1 2026
Dogwood Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Dogwood Therapeutics Quarterly report: Q1 2026
Dogwood Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
Dogwood Therapeutics Slides: Corporate presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today...
Dogwood Therapeutics Proxy statement: Proxy filing
Dogwood Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royal...
Dogwood Therapeutics Proxy statement: Proxy filing
Dogwood Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...
Dogwood Therapeutics Annual report: Q4 2025
Dogwood Therapeutics has published its Q4 2025 annual report on March 18, 2026.
Dogwood Therapeutics Earnings release: Q4 2025
Dogwood Therapeutics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, ...
Dogwood Therapeutics Proxy statement: Proxy Filing
Dogwood Therapeutics filed a proxy statement on February 13, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeut...
Dogwood Therapeutics Slides: Investor presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 26, 2026.
Dogwood Therapeutics Proxy statement: Proxy Filing
Dogwood Therapeutics filed a proxy statement on January 23, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood Therapeutics Registration statement: Registration Filing
Dogwood Therapeutics filed a registration statement on January 15, 2026, providing details about a securities offering with the SEC.
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neur...
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®- - New Synthetic Process to be Used for Phase 3 Development Prov...
Dogwood Therapeutics Transcript: EGM 2025
Five proposals, including stock conversions and an equity plan, were presented and approved by majority vote. No questions were raised, and all voting procedures complied with legal and NASDAQ requirements. Final results will be filed with the SEC.
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dog...
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release -
Dogwood Therapeutics Quarterly report: Q3 2025
Dogwood Therapeutics has published its Q3 2025 quarterly earnings report on November 6, 2025.